Addressing significant unmet patient needs
At Insmed, we are advancing clinical development programs that have the potential to make a significant impact on their respective disease landscapes. Every program we bring forward is driven by our desire to address significant patient needs that are not adequately being met today.
Amikacin Liposome Inhalation Suspension
We’re investigating amikacin liposome inhalation suspension for the treatment of NTM lung disease caused by MAC in a frontline setting of newly diagnosed patients.
We’re investigating brensocatib, a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), as a potential treatment for neutrophil-mediated diseases, including bronchiectasis and cystic fibrosis. Brensocatib is an investigational product that has not been approved for any indication in any jurisdiction.
We’re investigating treprostinil palmitil inhalation powder (TPIP), a dry powder formulation of treprostinil palmitil, as a potential therapy for rare pulmonary disorders, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. TPIP is an investigational product that has not been approved for any indication in any jurisdiction.
Translational medicine encompasses the early-stage research that will fuel our pipeline for years to come. Our focus on translational medicine leverages our research efforts to inform clinical development while harnessing real-world feedback to identify research pathways that will have the greatest impact on patients. Important to this work is the early identification and validation of pre-clinical targets that will enable us to continue to develop novel and cutting-edge technologies that may address a broad range of rare diseases across therapeutic areas.